LCB10 0200

Drug Profile

LCB10 0200

Alternative Names: GT-1; LCB10-0200

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LegoChem Biosciences
  • Developer Geom Therapeutics; LegoChem Biosciences
  • Class Antibacterials; Cephalosporins; Small molecules
  • Mechanism of Action Cell wall inhibitors; Penicillin-binding protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gram-negative infections

Most Recent Events

  • 13 Sep 2017 Geom Therapeutics plans a phase I trial in Healthy volunteers in USA, in 2018
  • 13 Sep 2017 Geom Therapeutics intends to submit an IND to the US FDA for Gram-negative infections in 2H 2017
  • 13 Sep 2017 Geom Therapeutics enters into Clinical Trial agreement with the National Institute of Allergy and Infectious Diseases for phase I trial of LCB10 0200
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top